Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Aaron Lubetsky, MD, Uri Martinowitz, MD, Toshko Lissitchkov, MD, Christine Voigt, PhD, Denise Wolko, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 1096.

https://doi.org/10.1182/blood.V126.23.1096.1096

Published: 2015

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

K John Pasi, Pencho Georgiev, Tim Mant, Michael Desmond Creagh, Toshko Lissitchkov, MD, David Bevan, Steve Austin, Charles R Hay, Brigit Brand, Rashid Kazmi, Pratima Chowdary, Margaret V Ragni, Jihong Chen, Akin Akinc, Benny Sorensen, Savita Rangarajan

Blood (2015) 126 (23): 551.

https://doi.org/10.1182/blood.V126.23.551.551

Published: 2015

Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD

Blood (2015) 126 (23): 547.

https://doi.org/10.1182/blood.V126.23.547.547

Published: 2015

Journal Articles

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Aaron Lubetsky, MD MSc, Toshko Lissitchkov, MD, Elena Santagostino, MD, PhD, Gantcho Jotov, MD, Tami Barazani-Brutman, Ph.D, Christine Voigt, Ph.D, Tina Moises, Ph.D, Iris C. Jacobs, MD, Uri Martinowitz, MD

Blood (2013) 122 (21): 1109.

https://doi.org/10.1182/blood.V122.21.1109.1109

Published: 2013

Journal Articles

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Sigurd Knaub, PhD, Toshko Lissitchkov, MD, PhD, Kingsley Hampton, Mario Von Depka, Savita Rangarajan, MBBS, FRCP, FRCPath, Charles R.M. Hay, MD, FRCP, FRCPath, Edward GD Tuddenham, MBBS, FRCP, FRCPath, PhD, Peter Collins, MD, Katharina Holstein, MD, Angela Huth-Kühne, Ingrid Pabinger, MD, Johannes Oldenburg, MD, Johann Bichler

Blood (2012) 120 (21): 1132.

https://doi.org/10.1182/blood.V120.21.1132.1132

Published: 2012

Journal Articles

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Jerzy Windyga, MD, PhD, Toshko Lissitchkov, MD, PhD, Oleksandra Stasyshyn, MD, Vasily Mamonov, MD, Luminita Rusen, MD, PhD, José Luis Lamas, MD, Myungshin Oh, PhD, Miranda Chapman, Sandor Fritsch, PhD, Borislava G Pavlova, PhD, Wing Yen Wong, MD, Brigitt E. Abbuehl, MD

Blood (2012) 120 (21): 2222.

https://doi.org/10.1182/blood.V120.21.2222.2222

Published: 2012

Journal Articles

A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,

Sigurd Knaub, PhD, Andreas Tiede, MD, PhD, Toshko Lissitchkov, MD, PhD, Leonard A. Valentino, MD, FAAP, Jerry Sherman Powell, MD, Marilyn J. Manco-Johnson, MD

Blood (2011) 118 (21): 3309.

https://doi.org/10.1182/blood.V118.21.3309.3309

Published: 2011

Journal Articles

Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Marina Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Françoise Huguet, MD, Ilaria Del Guidice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo

Blood (2010) 116 (21): 2449.

https://doi.org/10.1182/blood.V116.21.2449.2449

Published: 2010

Journal Articles

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, MD, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Francoise Huguet, MD, Ilaria Del Giudice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo, MD

Blood (2009) 114 (22): 2367.

https://doi.org/10.1182/blood.V114.22.2367.2367

Published: 2009

NARROW

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only